US health care predictions from Steven Burrill

24 December 2014
biosimilars_samples_large

US politics will continue to be characterized by partisanship as the Republican majorities in the House and Senate will look to dismantle unpopular aspects of the Patient Protection and Affordable Care Act, the Obama Administration’s landmark health care reform legislation, says Steven Burrill, chief executive of Burrill LLC and Burrill Media in his annual predictions for the life sciences in the new year.

With the power of the veto in President Obama’s hands, serious threats to the law are more likely to come from the judiciary rather than the legislative branch. A decision to come in 2015 in King v Burwell, a case that challenges the legality of tax credits to people who purchased health insurance in 34 states that did not establish their own health exchanges under the law, could affect care to 4.5 million people.

In emerging markets, though, the health care systems of the future will begin to emerge as rapid change will be enabled by new technology. Rather than modernizing existing structures and technology to meet their needs, these systems are being built around new digital technologies that will provide decentralized models of delivery and capitalize on mobile and point-of-care diagnostics.

Biosimilars

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biosimilars